Special Educational Event in Support of 2020 World Thrombosis Day
Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of blood clots in the venous system, a complication known as venous thromboembolism (VTE). Laboratory-based diagnostic assays, including automated D-dimer tests, can greatly help with clinician management of VTE, especially prevention of blood clots in the lungs, known as pulmonary embolism (PE). Our webinar will provide an overview of previously published trials featuring the role of D-dimer to identify patients at high risk of VTE in the medically ill population, published clinical algorithms to stratify patient risk, as well as breaking literature around management of VTE in medically ill COVID-19 patients.
Learning Objectives
- Understand the new role of elevated D-dimer as a predictor of venous thromboembolic (VTE) risk in hospitalized medically ill patients
- Assess novel data about elevated D-dimers in predicting poor outcomes and risk of thrombosis in hospitalized COVID-19 patients
- Review the incorporation of D-dimer in novel VTE risk scores
- Understand how elevated D-dimers can be used to identify patients with a net clinical benefit of extended thromboprophylaxis post hospital discharge